sellStrong cluster of 9
James Warren Huff sold $6.4M of RETA
Chief Executive Officer at REATA PHARMACEUTICALS INC. 75,000 shares at an average of $85.46, traded Mar 2, 2023, filed Mar 3, 2023.
Warning score
85Value
$6.4M
75,000 shares
Holdings after
36,158
-67% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +25Trade size$6.4M at market
- +20Share of holdings soldSold 67% of holdings
- +15Cluster9 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001209191-23-015713, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 1, 2023 | CConversion Class A common stock | +75,000 | - | - | 111,158 | Mar 3, 2023 |
| Mar 2, 2023 | SOpen-market sale Class A common stock | -8,104 | $81.49 | $660k | 103,054 | Mar 3, 2023 |
| Mar 2, 2023 | SOpen-market sale Class A common stock | -12,132 | $82.20 | $997k | 90,922 | Mar 3, 2023 |
| Mar 2, 2023 | SOpen-market sale Class A common stock | -9,660 | $83.31 | $805k | 81,262 | Mar 3, 2023 |
| Mar 2, 2023 | SOpen-market sale Class A common stock | -7,439 | $84.33 | $627k | 73,823 | Mar 3, 2023 |
| Mar 2, 2023 | SOpen-market sale Class A common stock | -6,395 | $85.25 | $545k | 67,428 | Mar 3, 2023 |
| Mar 2, 2023 | SOpen-market sale Class A common stock | -3,475 | $86.44 | $300k | 63,953 | Mar 3, 2023 |
| Mar 2, 2023 | SOpen-market sale Class A common stock | -4,034 | $87.61 | $353k | 59,919 | Mar 3, 2023 |
| Mar 2, 2023 | SOpen-market sale Class A common stock | -12,826 | $88.59 | $1.1M | 47,093 | Mar 3, 2023 |
| Mar 2, 2023 | SOpen-market sale Class A common stock | -5,742 | $89.49 | $514k | 41,351 | Mar 3, 2023 |
| Mar 2, 2023 | SOpen-market sale Class A common stock | -4,623 | $90.57 | $419k | 36,728 | Mar 3, 2023 |
| Mar 2, 2023 | SOpen-market sale Class A common stock | -570 | $91.12 | $52k | 36,158 | Mar 3, 2023 |
| Mar 1, 2023 | CConversion Class B common stockderivative | -75,000 | - | - | 212,903 | Mar 3, 2023 |
Related signals
Other insiders at REATA PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 57Moderate | REATA PHARMACEUTICALS INC | Dawn Carter Bir Chief Commercial Officer | $808k 9,317 shares | -22% | |
| 53Moderate | REATA PHARMACEUTICALS INC | Shamim Ruff director | $481k 5,740 shares | -52% | |
| 50Moderate | REATA PHARMACEUTICALS INC | Andrea Loewen SVP, Global Regulatory Affairs | $1.6M 19,036 shares | -33% | |
| 30Weak | REATA PHARMACEUTICALS INC | Bhaskar Anand SVP, Chief Accounting Officer | $14k 165 shares | -1% | |
| 60Notable | REATA PHARMACEUTICALS INC | Dawn Carter Bir Chief Commercial Officer | $8.5M 96,996 shares | -100% | |
| 45Moderate | REATA PHARMACEUTICALS INC | Samina Khan SVP, Chief Medical Officer | $331k 3,961 shares | -9% | |
| 37Weak | REATA PHARMACEUTICALS INC | Colin John Meyer Chief Innovation Officer | $53k 621 shares | -1% | |
| 36Weak | REATA PHARMACEUTICALS INC | Michael D Wortley Chief Legal Officer | $35k 414 shares | -1% | |
| 44Moderate | REATA PHARMACEUTICALS INC | Manmeet Singh Soni COO, CFO and President | $53k 622 shares | -1% | |
| 38Weak | REATA PHARMACEUTICALS INC | Bhaskar Anand SVP, Chief Accounting Officer | $72k 820 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.